https://www.thebodypro.com/category/switching-stopping-hiv-treatment-pro/tag/croi-conference-on-retroviruses-and-opportunistic-infections
Switching or Stopping HIV Treatment

CROI (Conference on Retroviruses and Opportunistic Infections)

The Latest

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses Img

Bictegravir at CROI 2018: Switching Studies and Drug Resistance Analyses

Reports about bictegravir, the most recently approved integrase inhibitor, were included in an oral presentation and in several posters at CROI 2018.

Josep Llibre

Two-Drug Regimen Shines in HIV Treatment Switch Study

A regimen consisting of only two drugs, the integrase inhibitor dolutegravir (Tivicay) and the NNRTI rilpivirine (Edurant), held up well as a maintenance approach in people with HIV who switched from more complex regimens.

Dosing Regimen of 5 Days On and 2 Days Off Controls HIV in Young People Img

Dosing Regimen of 5 Days On and 2 Days Off Controls HIV in Young People

A study showed viral control in the great majority of youth who took their regimen for five days but then skipped two, which may offer younger patients a novel way to keep HIV under control while addressing common adherence issues.

Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients Img

Markers of Immune Exhaustion Predict Post-Treatment Control in HIV Patients

Biomarkers of immune exhaustion were associated with how long a patient was able to control HIV after treatment was interrupted, according to a study presented at CROI 2015.

Promo Image

TILT: A Look at the Role of Interleukin-2 in Treatment Interruption Leans Toward the Negative

Most antiretroviral treatment guidelines utilize a CD4+ cell count threshold for the initiation of therapy. Interventions that increase CD4+ cell counts may not only be clinically beneficial, they may also be able to prolong the time off of antiretro...